IP Library Granted Patent US 7,894,992
Granted Patent B2
US 7,894,992 · App. 10/409,004 · Granted Feb 22, 2011

Diagnosis and classification of multiple myeloma

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,894,992
App. No.
10/409,004
Granted
Feb 22, 2011
Kind
B2
Abstract

Gene expression profiling between normal B cells/plasma cells and multiple myeloma cells revealed four distinct subgroups of multiple myeloma plasma cells that have significant correlation with clinical characteristics known to be associated with poor prognosis. Diagnosis for multiple myeloma (and possibly monoclonal gammopathy of undetermined significance) based on differential expression of 14 genes, as well as prognostics for the four subgroups of multiple myeloma based on the expression of 24 genes were also established. Gene expression profiling also allows placing multiple myeloma into a developmental schema parallel to that of normal plasma cell differentiation. The development of a gene expression- or developmental stage-based classification system for multiple myeloma would lead to rational design of more accurate and sensitive diagnostics, prognostics and tumor-specific therapies for multiple myeloma.

Claims (16)

1. A method of identifying a group of genes that can distinguish between normal plasma cells and plasma cells of multiple myeloma, comprising:

isolating plasma cells from bone marrow of individuals who do not have multiple myeloma and from bone marrow of individuals with multiple myeloma:

purifying said plasma cells by CD138 selection;

isolating total RNA from said plasma cells;

hybridizing said total RNA to a DNA microarray; and

identifying differential gene expression patterns that are statistically significant; and

applying hierarchical clustering analysis to identify a group of genes wherein said group of genes is capable of accurate discrimination between normal plasma cells and plasma cells of multiple myeloma.

2. The method of claim 1 , wherein one said gene has SEQ ID NO: 3.

3. The method of claim 1 , wherein said group of genes is capable of accurate discrimination between four subgroups of multiple myeloma.

4. A method of identifying a group of genes that can distinguish between four subgroups of multiple myeloma, wherein one said gene has SEQ ID NO: 3, comprising:

isolating plasma cells bone marrow of individuals who do not have multiple myeloma and from bone marrowpydividuals with multiple myeloma:

purifying said plasma cells by C0138 selection:

isolating total RNA from said plasma cells:

hybridizing said total RNA to a DNA microarray; and

identifying differential gene expression patterns that are statistically significant and

applying hierarchical clustering analysis to identify a group of genes wherein said group of genes, wherein one said gene has SEQ ID NO: 3, is capable of accurate discrimination between four subgroups of multiple myeloma.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2017
From: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
To: BIOVENTURES, LLC
Reel/Frame 043283/0468 →
RE-RECORD TO CORRECT THE NAME OF THE ASSINGEE, PREVIOUSLY RECORDED ON REEL 014103 FRAME 0594. Recorded Dec 23, 2010
From: SHAUGHNESSY, JOHN D.; BARLOGIE, BART; ZHAN, FENGHUANG
To: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Reel/Frame 025641/0890 →
CONFIRMATORY LICENSE Recorded Feb 11, 2009
From: UNIVERSITY OF ARKANSAS MED SCIS LTL ROCK
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 022239/0356 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2003
From: SHAUGHNESSY, JOHN D.; BARLOGIE, BART; ZHAN, FENGHUANG
To: UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, THE
Reel/Frame 014103/0594 →